Pay in 4 interest-free payments of $7.34 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
March 18, 2009
(Nasdaq: GUTS) (the Company or Fractyl), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced groundbreaking results from the REMAIN-1 Midpoint Cohort, supporting the potential for Revita to be the first therapy to preserve weight loss after GLP-1 drug discontinuation
Studies show that this formula helps reduce the visibility of pigmentation by nearly half and corrects melanin levels on the skins surface by more than a third, working in harmony with the epidermiss natural renewal cycles
They are not interchangeable and should not be used outside their approved indications
